• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基因型抑制商数和（累积）突变数量可预测洛匹那韦治疗的反应。

The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapy.

作者信息

Hoefnagel Jolanda G M, van der Lee Manon J, Koopmans Peter P, Schuurman Rob, Jurriaans Suzanne, van Sighem Ard I, Gras Luuk, de Wolf Frank, Galama Jochem M D, Burger David M

机构信息

Department of Medical Microbiology, Nijmegen University Centre for Infectious Diseases, the Netherlands.

出版信息

AIDS. 2006 Apr 24;20(7):1069-71. doi: 10.1097/01.aids.0000222083.44411.02.

DOI:10.1097/01.aids.0000222083.44411.02
PMID:16603863
Abstract

For 95 protease inhibitor-experienced HIV-1-infected patients, the genotypic inhibitory quotient (GIQ; trough level/number of mutations) was calculated for lopinavir. Three different sets of mutations showed equal predictive value. However, the use of cumulative numbers of mutations for calculation of the GIQ showed significantly better association with the virological response. Furthermore, the predictive value of the GIQ was no different from that of the number of mutations alone.

摘要

对于95例有蛋白酶抑制剂治疗经验的HIV-1感染患者，计算了洛匹那韦的基因型抑制商（GIQ；谷浓度/突变数）。三组不同的突变显示出相同的预测价值。然而，使用突变累积数来计算GIQ与病毒学反应的关联性显著更好。此外，GIQ的预测价值与仅使用突变数的预测价值并无差异。

相似文献

1
The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapy.基因型抑制商数和（累积）突变数量可预测洛匹那韦治疗的反应。
AIDS. 2006 Apr 24;20(7):1069-71. doi: 10.1097/01.aids.0000222083.44411.02.
2
Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.不同洛匹那韦基因型抑制商数预测接受洛匹那韦/利托那韦治疗的高治经验HIV感染患者48周病毒学应答的能力。
J Med Virol. 2006 Dec;78(12):1537-41. doi: 10.1002/jmv.20736.
3
The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.耐药性算法和基因型抑制商在预测曾接受过1型人类免疫缺陷病毒蛋白酶抑制剂治疗的患者中洛匹那韦-利托那韦治疗反应中的应用。
J Clin Virol. 2007 Feb;38(2):131-8. doi: 10.1016/j.jcv.2006.11.011. Epub 2007 Jan 4.
4
Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.对于初治洛匹那韦且既往蛋白酶抑制剂暴露有限的患者，通过洛匹那韦基因型抑制商预测早期和确诊病毒学应答。
J Clin Virol. 2006 Apr;35(4):414-9. doi: 10.1016/j.jcv.2005.10.001. Epub 2005 Nov 8.
5
Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.预测在大量使用蛋白酶抑制剂的患者中对洛匹那韦-利托那韦反应的病毒学和药理学参数。
Antimicrob Agents Chemother. 2005 May;49(5):1720-6. doi: 10.1128/AAC.49.5.1720-1726.2005.
6
Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.在有抗逆转录病毒治疗经验的HIV感染患者中，药物水平、HIV基因分型及基因型抑制商（GIQ）对沙奎那韦/利托那韦治疗反应的预测价值。
J Med Virol. 2005 Dec;77(4):460-4. doi: 10.1002/jmv.20477.
7
Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.临床实践中HIV蛋白酶抑制剂阿扎那韦的治疗药物监测
J Antimicrob Chemother. 2007 Oct;60(4):897-900. doi: 10.1093/jac/dkm298. Epub 2007 Aug 17.
8
Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.HIV-1蛋白酶突变I47A在临床实践中的流行情况及其与洛匹那韦耐药性的关联。
AIDS. 2006 Apr 24;20(7):1071-4. doi: 10.1097/01.aids.0000222084.44411.cc.
9
Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.在接受过广泛治疗的患者中，使用沙奎那韦和洛匹那韦的强化双重HIV蛋白酶抑制剂疗法疗效的预测因素。
Antivir Ther. 2007;12(8):1237-46.
10
Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient.使用基因型抑制商预测洛匹那韦/利托那韦的病毒学反应。
AIDS Res Hum Retroviruses. 2004 Mar;20(3):275-8. doi: 10.1089/088922204322996509.

引用本文的文献

1
Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIV.利用治疗药物监测数据优化儿童抗逆转录病毒药物的给药建议和治疗管理，以治疗 HIV 感染者。
Ther Drug Monit. 2019 Aug;41(4):431-443. doi: 10.1097/FTD.0000000000000637.
2
A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study.一项评估抗逆转录病毒治疗经验丰富的HIV感染者中基于蛋白酶抑制剂方案的治疗药物监测（TDM）的随机临床试验：A5146研究第48周结果
HIV Clin Trials. 2011 Jul-Aug;12(4):201-14. doi: 10.1310/hct1204-201.
3
Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy.
在先前接受蛋白酶抑制剂（PI）治疗失败的人类免疫缺陷病毒感染受试者中，药代动力学调整后的表型敏感性对利托那韦增强型蛋白酶抑制剂（PI）反应的预测价值。
Antimicrob Agents Chemother. 2009 Jun;53(6):2335-41. doi: 10.1128/AAC.01387-08. Epub 2009 Mar 23.
4
A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients.在有抗逆转录病毒治疗经验的HIV-1感染患者中进行蛋白酶抑制剂治疗药物监测的随机试验。
AIDS. 2009 Jan 28;23(3):357-68. doi: 10.1097/QAD.0b013e32831f9148.
5
Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen.在接受利托那韦增强的双蛋白酶抑制剂治疗方案且治疗史复杂的患者中，人类免疫缺陷病毒表型和基因型以及安普那韦和洛匹那韦抑制商数的预测价值。
Antimicrob Agents Chemother. 2008 May;52(5):1642-6. doi: 10.1128/AAC.01314-07. Epub 2008 Feb 19.